BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31092287)

  • 1. Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.
    Qi J; Esfahani DR; Huang T; Ozark P; Bartom E; Hashizume R; Bonner ER; An S; Horbinski CM; James CD; Saratsis AM
    Acta Neuropathol Commun; 2019 May; 7(1):75. PubMed ID: 31092287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
    Dorris K; Sobo M; Onar-Thomas A; Panditharatna E; Stevenson CB; Gardner SL; Dewire MD; Pierson CR; Olshefski R; Rempel SA; Goldman S; Miles L; Fouladi M; Drissi R
    J Neurooncol; 2014 Mar; 117(1):67-76. PubMed ID: 24477622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
    Carceller F; Fowkes LA; Khabra K; Moreno L; Saran F; Burford A; Mackay A; Jones DT; Hovestadt V; Marshall LV; Vaidya S; Mandeville H; Jerome N; Bridges LR; Laxton R; Al-Sarraj S; Pfister SM; Leach MO; Pearson AD; Jones C; Koh DM; Zacharoulis S
    J Neurooncol; 2016 Aug; 129(1):109-21. PubMed ID: 27180091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.
    Saratsis AM; Kambhampati M; Snyder K; Yadavilli S; Devaney JM; Harmon B; Hall J; Raabe EH; An P; Weingart M; Rood BR; Magge SN; MacDonald TJ; Packer RJ; Nazarian J
    Acta Neuropathol; 2014; 127(6):881-95. PubMed ID: 24297113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.
    Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM
    J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.
    Lin GL; Nagaraja S; Filbin MG; Suvà ML; Vogel H; Monje M
    Acta Neuropathol Commun; 2018 Jun; 6(1):51. PubMed ID: 29954445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Long Non-Coding RNA H19 Drives the Proliferation of Diffuse Intrinsic Pontine Glioma with H3K27 Mutation.
    Roig-Carles D; Jackson H; Loveson KF; Mackay A; Mather RL; Waters E; Manzo M; Alborelli I; Golding J; Jones C; Fillmore HL; Crea F
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.
    Ahsan S; Raabe EH; Haffner MC; Vaghasia A; Warren KE; Quezado M; Ballester LY; Nazarian J; Eberhart CG; Rodriguez FJ
    Acta Neuropathol Commun; 2014 Jun; 2():59. PubMed ID: 24894482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenascin-C Function in Glioma: Immunomodulation and Beyond.
    Yalcin F; Dzaye O; Xia S
    Adv Exp Med Biol; 2020; 1272():149-172. PubMed ID: 32845507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone H3.3K27M Represses
    Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
    Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
    Liao Y; Luo Z; Deng Y; Zhang F; Rao R; Wang J; Xu L; Kumar SS; Sengupta S; DeWire-Schottmiller M; Berry K; Garrett M; Fouladi M; Drissi R; Lu QR
    Neuro Oncol; 2021 Jul; 23(7):1183-1196. PubMed ID: 33539525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid.
    Saratsis AM; Yadavilli S; Magge S; Rood BR; Perez J; Hill DA; Hwang E; Kilburn L; Packer RJ; Nazarian J
    Neuro Oncol; 2012 May; 14(5):547-60. PubMed ID: 22492959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
    Hummel TR; Salloum R; Drissi R; Kumar S; Sobo M; Goldman S; Pai A; Leach J; Lane A; Pruitt D; Sutton M; Chow LM; Grimme L; Doughman R; Backus L; Miles L; Stevenson C; Fouladi M; DeWire M
    J Neurooncol; 2016 Mar; 127(1):53-61. PubMed ID: 26626490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
    Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
    Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.